A5083642995- Radiopharmaceutical Chemistry and Applications
- Neuroendocrine Tumor Research Advances
- Prostate Cancer Treatment and Research
- Lung Cancer Research Studies
- Neuroblastoma Research and Treatments
- Peptidase Inhibition and Analysis
- Medical Imaging Techniques and Applications
- Hydrology and Watershed Management Studies
- Prostate Cancer Diagnosis and Treatment
- Hydrology and Drought Analysis
- Bone health and treatments
- Monoclonal and Polyclonal Antibodies Research
- Flood Risk Assessment and Management
- Climate variability and models
- Glycosylation and Glycoproteins Research
- Renal cell carcinoma treatment
- Thyroid Cancer Diagnosis and Treatment
- Cancer-related gene regulation
- Marine and environmental studies
- Cancer, Lipids, and Metabolism
- Medical Imaging and Pathology Studies
- Photodynamic Therapy Research Studies
- Radioactive Decay and Measurement Techniques
- Cancer Immunotherapy and Biomarkers
- Rheumatoid Arthritis Research and Therapies
National Institute of Meteorology
2023-2024
National Institute of Meteorology and Hydrology
2022-2024
St. Marien-Hospital Bonn
2020-2023
Bulgarian Academy of Sciences
2014-2022
Behörde für Gesundheit und Verbraucherschutz
2022
Institute of Molecular Biology
2019-2021
University Hospital Bonn
2016-2021
Klinikum Westfalen (Germany)
2021
Heinrich Heine University Düsseldorf
2020
Düsseldorf University Hospital
2020
Prostate-specific membrane antigen (PSMA) is highly expressed on prostate epithelial cells and strongly up-regulated in cancer (PC), making it an optimal target for the treatment of metastasized PC. Radioligand therapy (RLT) with 177Lu-PSMA-DKFZ-617 (Lu-PSMA) a targeted metastatic In this study, we retrospectively analyzed side effects response rate 24 hormone and/or chemorefractory PC patients mean age 75.2 years (range: 64-82) distant metastases progressive disease according to PSA level,...
Radiolabeled prostate-specific membrane antigen (PSMA) ligands represent a true theranostic concept for diagnosis and therapy in patients with relapsed or metastatic prostate cancer. The aim of this study was to evaluate the response tolerability single dose <sup>177</sup>Lu-PSMA-617 large cohort castration-resistant cancer (mCRPC). <b>Methods:</b> data 82 consecutive (median age, 73 y; range, 43–87 y) mCRPC who received (mean, 5.9 ± 0.5 GBq) were retrospectively analyzed. Data collected at...
Radioligand therapy (RLT) with 177Lu-PSMA-617 (PSMA is prostate-specific membrane antigen) a novel targeted for metastatic prostate cancer. In this study, we evaluated the effect of different pretherapeutic parameters on therapeutic response measured by antigen (PSA) 2 mo after RLT.RLT was performed in 40 hormone-refractory patients distant metastases and progressive disease (mean age, 71.4 y). 68Ga-PSMA-11 PET/CT all 1-2 wk before RLT. All were treated mean 6 GBq. The SUVmax tumor lesions...
// Hojjat Ahmadzadehfar 1, * , Stephan Schlolaut Rolf Fimmers 2 Anna Yordanova 1 Stefan Hirzebruch Carl Schlenkhoff Florian C. Gaertner Zool Hilmi Awang Hauser 3 and Markus Essler Department of Nuclear Medicine, University Hospital Bonn, Germany Institute for Medical Biometry, Informatics Epidemiology, Urology, These authors contributed equally to this work Correspondence to: Ahmadzadehfar, email: hojjat.ahmadzadehfar@ukb.uni-bonn.de Keywords: 177 Lu, overall survival, PSMA, radioligand...
Radioligand therapy with 177Lu-PSMA-617 is an innovative and effective for castrate-resistant metastatic prostate cancer patients. For patients symptomatic bone metastases without visceral metastases, the guidelines recommend radionuclide 223Ra-dichloride as a single therapeutic agent or in combination hormone therapy. The aim of this study was to evaluate safety repeated cycles after exposure more 223Ra. Forty-nine were treated three Lu-PSMA-617 divided into two groups subjected history...
Abstract Purpose: Although somatostatin analogues (SSA) and peptide receptor radionuclide therapy (PRRT) are validated therapies in patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NET), it remains unclear whether SSA combined PRRT or as maintenance can provide prolonged survival compared treated alone. In this retrospective study, we aimed to investigate there is a benefit adding combination and/or therapy. Patients Methods: The investigation included 168...
Purpose Combinations of therapies may enhance therapeutic effects without significantly increasing the incidence adverse events. However, there are few data regarding survival after concomitant chemotherapy and peptide receptor radionuclide therapy (PRRT) with [ 177 Lu]Lu-octreotate in patients neuroendocrine tumors (NETs). Thus, we explored outcome this combination therapies. Methods Fifteen somatostatin receptor–positive, rapidly progressive G2/G3 NETs during or PRRT alone from 2 German...
We retrospectively evaluated the utility of <sup>68</sup>Ga-PSMA-11 PET for planning <sup>223</sup>RaCl<sub>2</sub> therapy patients with metastatic prostate cancer and its impact on therapeutic response as determined by prostate-specific antigen (PSA) alkaline phosphatase (ALP), well correlation PSA changes results membrane (PSMA) follow-up scans. <b>Methods:</b> Sixty-three a median age 73 y who underwent 307 cycles were analyzed. In 31 patients, bone scanning radiologic imaging performed...
Abstract Background Currently, prostate‐specific membrane antigen‐radioligand therapy (PSMA‐RLT) is considered a last‐line treatment option in advanced castration‐resistant prostate cancer. Despite these patients' poor prognosis, accurate estimation of their overall survival (OS) essential to determine whether benefits exist from the and loss valuable time unnecessary side effects can be avoided. The aim present study evaluate various biochemical markers predict OS men undergoing PSMA‐RLT...
Abstract Sorafenib is a small molecular inhibitor of several tyrosine protein kinases, including vascular endothelial growth factor receptor, platelet‐derived receptor and rapidly accelerated fibrosarcoma targeting signal transduction angiogenic pathways. It approved for the treatment advanced renal cell carcinoma hepatocellular carcinoma. The objectives this prospective phase II trial were to assess activity tolerability sorafenib in patients with recurrent or refractory myeloma. In total,...
The importance of personalized medicine is growing, since there an urged need to avoid unnecessary and expensive treatments. In nuclear medicine, the theranostic approach established tool for a specific molecular targeting in means diagnostics therapy. visualisation potential targets can help predict if patient would benefit from particular treatment or not. Thanks quick development radiopharmaceuticals diagnostic techniques, use agents constantly rising. this article important milestones...
A 64-year-old man with prostate cancer and an increasing prostate-specific antigen (PSA) level under therapy abiraterone acetate underwent a Ra. Before the first 4 weeks after last cycle, patient Ga-PSMA PET, which showed clear response of bone metastases.
[99mTc]Tc-Sestamibi (MIBI) is an increasingly used tool for evaluation of thyroid nodules. However, there a lack evidence about the accuracy this method in European population. The aim study was to assess utility MIBI differentiation nodules large cohort. 161 patients underwent MIBI, followed by thyroidectomy. We dual phase protocol. Interpretation images included scoring system from 0 (absent) 3 (increased); provide scale uptake nodule comparison paranodular tissue. Additionally, we...